Development of novel agents for bladder cancer

Update on cancer therapeutics Pub Date : 2009-05-01 DOI:10.1016/j.uct.2009.04.001

Noah M. Hahn , Thomas Powles , Christopher J. Sweeney

{"title":"Development of novel agents for bladder cancer","authors":"Noah M. Hahn , Thomas Powles , Christopher J. Sweeney","doi":"10.1016/j.uct.2009.04.001","DOIUrl":null,"url":null,"abstract":"<div><p>Traditional treatment options for bladder cancer include transurethral resection and intravesical Bacillus Calmette Guerin for early stage disease and cystectomy or radiation therapy (with or without chemotherapy) for muscle-invasive disease. Platinum-based chemotherapy improves patient outcomes in both the perioperative and metastatic setting. Despite an increase in new therapeutic options over the past decade for many cancer patients, similar advances in bladder cancer are limited. In recent years, an improved understanding of the molecular forces driving bladder cancer development and progression has unfolded. These discoveries create a set of innovative therapeutic opportunities in bladder cancer. This review examines novel anti-cancer agents currently in clinical trials with preclinical rationale to support evaluation in bladder cancer. In addition, strategies to match a patient's tumor to the most appropriate agent are discussed. This may provide a more rational approach to evaluating the role of emerging anti-cancer agents in bladder cancer.</p></div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2009-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2009.04.001","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Update on cancer therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1872115X09000164","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Traditional treatment options for bladder cancer include transurethral resection and intravesical Bacillus Calmette Guerin for early stage disease and cystectomy or radiation therapy (with or without chemotherapy) for muscle-invasive disease. Platinum-based chemotherapy improves patient outcomes in both the perioperative and metastatic setting. Despite an increase in new therapeutic options over the past decade for many cancer patients, similar advances in bladder cancer are limited. In recent years, an improved understanding of the molecular forces driving bladder cancer development and progression has unfolded. These discoveries create a set of innovative therapeutic opportunities in bladder cancer. This review examines novel anti-cancer agents currently in clinical trials with preclinical rationale to support evaluation in bladder cancer. In addition, strategies to match a patient's tumor to the most appropriate agent are discussed. This may provide a more rational approach to evaluating the role of emerging anti-cancer agents in bladder cancer.

查看原文本刊更多论文

新型膀胱癌药物的研究进展

膀胱癌的传统治疗方案包括早期疾病的经尿道切除和膀胱内卡介素芽孢杆菌，以及肌肉侵袭性疾病的膀胱切除术或放射治疗(有或没有化疗)。铂类化疗可改善围手术期和转移性肿瘤患者的预后。尽管在过去的十年中，许多癌症患者的新治疗选择有所增加，但膀胱癌的类似进展有限。近年来，人们对膀胱癌发生和发展的分子机制有了更深入的了解。这些发现为膀胱癌的治疗创造了一系列创新的机会。本文综述了目前在临床试验中具有临床前理论基础的新型抗癌药物，以支持膀胱癌评价。此外，还讨论了将患者肿瘤与最合适的药物匹配的策略。这可能为评价新型抗癌药物在膀胱癌中的作用提供一种更合理的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Update on cancer therapeutics

自引率

0.00%

发文量